Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05199987 Completed - Clinical trials for Severe Chronic Obstructive Pulmonary Disease

Breathing Control Exercises in Patients With Chronic Obstructive Pulmonary Disease.

Start date: January 31, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to test whether breathing control exercises embedded in occupational therapy sessions have an impact on quality of life and dyspnea in patients with chronic obstructive pulmonary disease (COPD).

NCT ID: NCT05199181 Completed - Clinical trials for Symptomatic Irreversible Pulpitis

Full Pulpotomy in Mature Teeth With Symptomatic Irreversible Pulpitis as a Routine Treatment in the Primary Care Clinics

Start date: November 19, 2019
Phase: N/A
Study type: Interventional

The present study has the objective of being a first approach of the full feasibility study in order to find out whether the Full Pulpotomy performed by a general practice dentist in a primary care dental clinic at the public health system with limited armamentarium could be suitable and present an appropriate success rate as well as patient satisfaction.

NCT ID: NCT05197634 Completed - COVID-19 Pandemic Clinical Trials

The Impact of Covid-19 Pandemic On The Children With Autism Spectrum Disorder

Start date: September 6, 2021
Phase:
Study type: Observational

The Covid-19 outbreak has caused families and individuals to change their life routines and eating habits, and has affected their psychology, especially for children with autism, due to the change in their routines. These psychological changes may trigger the self-harming behavior that is very common in children with autism. Dental trauma, a common problem in children and adolescents, can also be seen in individuals who need special care such as autism. The aim of this study is to evaluate the susceptibility of children with autism to orofacial trauma during the pandemic period and compare them with the pre-pandemic period and the healthy group, as well as to question the lifestyle, nutritional habits, mood changes and oral health behaviors that may be related to the risk of trauma.

NCT ID: NCT05197283 Completed - Appetitive Behavior Clinical Trials

Determining the Glycemic Effects of Three Types of Spaghetti

Start date: October 15, 2021
Phase: N/A
Study type: Interventional

This study investigated the effects of thee types of spaghetti No7 on the glycemic response

NCT ID: NCT05197075 Completed - Clinical trials for Human Immunodeficiency Virus (HIV)

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Start date: August 3, 2022
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the ability to swallow the Darunavir/Cobicistat (DRV/COBI) fixed dosed combination (FDC) tablet dispersed in water.

NCT ID: NCT05196971 Completed - Clinical trials for Treatment Resistant Depressive Disorder

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression

Start date: October 28, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of intranasal HS-10345 (84mg) compared with placebo in participants with treatment-resistant depression (TRD).

NCT ID: NCT05195528 Completed - Heartburn Clinical Trials

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

Start date: January 17, 2022
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to assess the efficacy of vonoprazan (10 mg and 20 mg once daily [QD]) compared to placebo (QD) in relief of heartburn over 4 weeks in participants with NERD.

NCT ID: NCT05194748 Completed - Clinical trials for Parkinson's Disease and Parkinsonism

Diaphragmatic Thickness and Pulmonary Function in Parkinson's Disease

Start date: December 24, 2021
Phase:
Study type: Observational [Patient Registry]

Ultrasound can give important information about the morphology of the diaphragm and the amount of contraction. Our aim, with the prediction that a restrictive pathology will occur in the pulmonary function with the addition of camptocormia in Parkinson's patients; to compare respiratory functions in Parkinson's patients with and without camptocormia, to investigate the correlation between ultrasonographically measured diaphragmatic thickness and pulmonary function test values.

NCT ID: NCT05194553 Completed - Metabolic Syndrome Clinical Trials

Identification and Characterization of NAFLD in Turkey

Start date: February 15, 2022
Phase:
Study type: Observational

Non-alcoholic fatty liver disease (NAFLD) is with 25% the most prevalent liver disorder in Western society and is associated with overweight, obesity, metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD). NAFLD is defined by a hepatic fat accumulation of more than 5% in the absence of classical causes of steatogenesis (e.g. alcohol and steatogenic drugs). It represents a broad spectrum of clinical entities from steatosis to advanced liver disease with hepatic failure. Most of the patients have simple steatosis, however in about 15-30% non-alcoholic steatohepatitis (NASH) develops, which leads to an overall increase in morbidity and mortality due to the progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Patients with NAFLD have no or few, mainly specific symptoms; and generally there is a silent progression of simple steatosis to NASH and in the end liver-related morbidity and mortality. Despite the clinical importance and the potential impact on healthcare resources, the majority of NAFLD patients are currently not detected due to the lack of non-invasive methods to diagnose NAFLD. To date, the prevalance of NAFLD in Turkey among subjects at risk, and its relation to common comorbidities such as obesity, T2DM and CVD is not clear. Therefore, identification of NAFLD patients in this cohort will give information on the prevalence in the group of uncomplicated overweight and obesity and those with concomitant cardiometabolic diseases. By early detecting these patients at risk to develop progressive liver diseases and extrahepatic manifestations, it will be possible to intervene and improve health. Within this context, this study aims to detect prevalence of NAFLD among risk groups. Also, the risk factors related to NAFLD etiology and progression, such as overweight, obesity, T2DM, CVD, diet and physical activity will be studied to have a better understanding of their presumed causal relationship with NAFLD.

NCT ID: NCT05193851 Completed - Clinical trials for Peripheral Nervous System Diseases

Evaluate the Safety and Pharmacokinetics of Ricolinostat

Start date: January 12, 2022
Phase: Phase 1
Study type: Interventional

This study is an open-label, phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.